ABC	Advanced Breast Cancer
ADC	Antibody-Drug Conjugate
AEs	Adverse Events
AI	Aromatase Inhibitor
Akt	Protein Kinase B
CDK4/6	Cyclin-Dependent Kinase 4/6
CNS	Central Nervous System
CrI	Credible Interval
DIC	Error Information Criterion
EMA	European Medicines Agency
Endo	Endocrine Therapy
ER+	Estrogen Receptor Positive
ErbB	Human Epidermal Growth Factor Receptor
HER2+	Epidermal Growth Factor Receptor 2 Positive
Her2-ADC	Anti-Her2 Antibody-Drug Conjugate
Her2-mAb	Anti-Her2 Monoclonal Antibody
Her2-tki	Anti-Her2 Tyrosine Kinase Inhibitor
HR	Hazard Ratio
HRs	Hormone Receptors
mAb	Monoclonal Antibody
MBC	Metastatic Breast Cancer
mTOR	Mammalian Target of Rapamycin
NCCN	National Comprehensive Cancer Network
NMA	Network Meta-Analysis
OR	Odds Ratio
ORR	Objective Response Rate
OS	Overall Survival
p-Akt	Phosphorylated Akt
PD-1	Programmed Death 1
PD-L1	Programmed Death Ligand 1
PFS	Progression-Free Survival
PR+	Progesterone Receptor Positive
SUCRA	Surface Under the Cumulative Ranking Curve
T-DM1	Trastuzumab Emtansine
T-DXd	Trastuzumab Deruxtecan
TKI	Tyrosine Kinase Inhibitor